Clinical Trial

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.
Trial Details
NCT Number NCT06739928
Lead Sponsor Guangzhou Institute of Respiratory Disease
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 120 participants
Start Date 2025-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-18